Animal models to explore the effects of CNS drugs on food intake and energy expenditure

Neuropharmacology

Volumn 63, Issue 1, 2012, Pages 124-131

  Vickers, Steven P ^a   Clifton, Peter G ^b  

^a RenaSci Ltd   (United Kingdom)

^b UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

Animal models; Energy expenditure; Food intake; Obesity

Indexed keywords

ANTIOBESITY AGENT; CENTRAL NERVOUS SYSTEM AGENTS; DEXAMPHETAMINE; EXENDIN 4; FENFLURAMINE; FLUOXETINE; LORCASERIN; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PIOGLITAZONE; RIMONABANT; SIBUTRAMINE; SITAGLIPTIN; TETRAHYDROLIPSTATIN; TOPIRAMATE;

DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EATING HABIT; ENERGY EXPENDITURE; EXPERIMENTAL MODEL; FOOD INTAKE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS; TREATMENT DURATION; WEIGHT CONTROL; WEIGHT REDUCTION;

ANIMALS; CENTRAL NERVOUS SYSTEM AGENTS; EATING; ENERGY METABOLISM; HUMANS; MODELS, ANIMAL;

EID: 84862133181     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.04.001     Document Type: Review

References (98)

1. A.R. Abubakari, W. Lauder, M.C. Jones, A. Kirk, C. Agyemang, and R.S. Bhopal Prevalence and time trends in diabetes and physical inactivity among adult West African populations, the epidemic has arrived Public. Health. 123 2009 602 614
2. D.B. Allison, J.L. Mentore, M. Heo, L.P. Chandler, J.C. Cappelleri, M.C. Infante, and P.J. Weiden Antipsychotic-induced weight gain, a comprehensive research synthesis Am. J. Psychiatry. 156 1999 1686 1696
3. J. Antin, J. Gibbs, J. Holt, R.C. Young, and G.P. Smith Cholecystokinin elicits the complete behavioral sequence of satiety in rats J. Comp. Physiol. Psychol. 89 1975 784 790
4. M. Apfelbaum, P. Vague, O. Ziegler, C. Hanotin, F. Thomas, and E. Leutenegger Long-term maintenance of weight loss after a very-low-calorie diet, a randomized blinded trial of the efficacy and tolerability of sibutramine Am. J. Med. 106 1999 179 184
5. M. Arnone, J. Maruani, F. Chaperon, M.H. Thiébot, M. Poncelet, P. Soubrié, and G. Le Fur Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors Psychopharmacology (Berl) 132 1997 104 106
6. S. Aronoff, S. Rosenblatt, S. Braithwaite, J.W. Egan, A.L. Mathisen, and R.L. Schneider Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes, a 6-month randomized placebo-controlled dose-response study Diabetes. Care. 23 2000 1605 1611
7. P. Aschner, M.S. Kipnes, J.K. Lunceford, M. Sanchez, C. Mickel, and D.E. Williams-Herman Sitagliptin study 021 group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes Diabetes. Care. 29 2006 2632 2637
8. C.J. Bailey, and P.R. Flatt Animals syndromes resembling type 2 diabetes J.C. Pickup, G. Williams, Textbook of Diabetes third ed. 2003 Blackwell Publishing Oxford 25.1 25.30
9. A.M. Barnfield, and P.G. Clifton Flavour aversions conditioned by dl-fenfluramine, a volume independent mechanism Psychopharmacology 98 1989 108 112
10. 2C receptor modulation and the treatment of obesity Diabetes. Obes. Metab. 1 1999 207 214
11. G.A. Bray, P. Hollander, S. Klein, R. Kushner, B. Levy, M. Fitchet, and B.H. Perry A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity Obes. Res. 11 2003 722 733
12. J.B. Buse, D.J. Drucker, K.L. Taylor, T. Kim, B. Walsh, and H. Hu DURATION-1, exenatide once weekly produces sustained glycaemic control and weight loss over 52 weeks Diabetes. Care. 33 2010 1255 1261
13. M. Cecchini, F. Sassi, J.A. Lauer, Y.Y. Lee, V. Guajardo-Barron, and D. Chisholm Tackling of unhealthy diets, physical inactivity, and obesity, health effects and cost-effectiveness Lancet 376 2010 1775 1784
14. P.G. Clifton, D.A. Popplewell, and M.J. Burton Feeding rate and meal patterns in the laboratory rat Physiol. Behav. 32 1984 369 374
15. P.G. Clifton, I.N. Rusk, and S.J. Cooper Effects of dopamine D1 and dopamine D2 antagonists on the free feeding and drinking patterns of rats Behav. Neurosci. 105 1991 272 281
16. P.G. Clifton Meal patterning in rodents: psychopharmacological and neuroanatomical studies Neurosci. Biobehav. Rev. 24 2000 213 222
17. G. Colombo, R. Agabio, G. Diaz, C. Lobina, R. Reali, and G.L. Gessa Appetite suppression and weight loss after the cannabinoid antagonist SR 141716 Life. Sci. 63 1998 113 117
18. I.P. Connoley, Y.L. Liu, I. Frost, I.P. Reckless, D.J. Heal, and M.J. Stock Thermogenic effects of sibutramine and its metabolites Br. J. Pharmacol. 126 1999 1487 1495
19. A.M. Cypess, and C.R. Kahn The role and importance of brown adipose tissue in energy homeostasis Curr. Opin. Pediatr. 22 2010 478 484
20. J.D. Davis, and G.P. Smith Analysis of the microstructure of the rhythmic tongue movements of rats ingesting maltose and sucrose solutions Behav. Neurosci. 106 1992 217 228
21. N. Davoodi, M. Kalinichev, S.A. Korneev, and P.G. Clifton Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine Psychopharmacology 203 2008 693 702
22. J. De Vry, G. Eckel, E. Kuhl, and R. Schreiber Effects of serotonin 5-HT(1) and 5-HT(2) receptor agonists in a conditioned taste aversion paradigm in the rat Pharmacol. Biochem. Behav. 66 2000 797 802
23. J.P. Després, A. Golay, and L. Sjöström Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia N. Engl. J. Med. 353 2005 2121 2134
24. K. Dickinson, T.J. North, G. Telford, S. Smith, R. Brammer, and R.B. Jones Determination of body composition in conscious adult female Wistar utilising total body electrical conductivity Physiol. Behav. 74 2001 425 433
25. G.N. Ervin, L.S. Birkemo, M.F. Johnson, L.K. Conger, J.T. Mosher, and J.A. Menius Jr. The effects of anorectic and aversive agents on deprivation-induced feeding and taste aversion conditioning in rats J. Pharmacol. Exp. Ther. 273 1995 1203 1210
26. B. Falissard, M. Mauri, K. Shaw, T. Wetterling, A. Doble, A. Giudicelli, and M. De Hert The METEOR study, frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs Int. Clin. Psychopharmacol. 2011 [Epub ahead of print]
27. A. Fisas, X. Codony, G. Romero, A. Dordal, J. Giraldo, R. Mercé, J. Holenz, N. Vrang, R.V. Sorensen, D. Heal, H. Buschmann, P.J. Pauwels, N. Vrang, and V. Sorensen Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats Br. J. Pharmacol. 148 2006 973 983
28. P.J. Fletcher Increased food intake in satiated rats induced by the 5-HT antagonists methysergide, metergoline and ritanserin Psychopharmacology (Berl) 96 1998 237 242
29. J.E. Foley, and J. Jordan Weight neutrality with the DPP-4 inhibitor, vildagliptin, mechanistic basis and clinical experience Vasc. Health. Risk. Manag. 6 2010 541 548
30. K.R. Fontaine, M. Heo, E.P. Harrigan, C.L. Shear, M. Lakshminarayanan, D.E. Casey, and D.B. Allison Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate Psychiatry. Res. 101 2001 277 288
31. K.M. Gadde, and D.B. Allison Combination therapy for obesity and metabolic disease Curr. Opin. Endocrinol. Diabetes. Obes. 16 2009 353 358
32. B.J. Goldstein, M.N. Feinglos, J.K. Lunceford, J. Johnson, and D.E. Williams-Herman Sitagliptin 036 study group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes Diabetes. Care. 30 2007 1979 1987
33. V. Golozoubova, F. Strauss, and K. Malmlöf Locomotion is the major determinant of sibutramine-induced increase in energy expenditure Pharmacol. Biochem. Behav. 83 2006 517 527
34. F.L. Greenway, K. Fujioka, R.A. Plodkowski, S. Mudaliar, M. Guttadauria, J. Erickson, D.D. Kim, E. Dunayevich, and COR-I Study Group Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I), a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet 376 2010 595 605
35. J.R. Hadcock, P.A. Carpino, P.A. Iredale, R.L. Dow, D. Gautreau, L. Thiede, D. Kelly-Sullivan, J.S. Lizano, X. Liu, J. Van Deusen, K.M. Ward, R.E. O'Connor, S.C. Black, D.A. Griffith, and D.O. Scott Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1(CB1) receptor antagonist BMC. Pharmacol. 10 2010 9
36. J.C. Halford, S.C. Wanninayake, and J.E. Blundell Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake Pharmacol. Biochem. Behav. 61 1998 159 168
37. J.A. Harrold, J.C. Elliott, P.J. King, P.S. Widdowson, and G. Williams Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity, a role for endogenous cannabinoids in driving appetite for palatable food? Brain. Res. 952 2002 232 238
38. A.W. Hartfield, N.A. Moore, and P.G. Clifton Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat Psychopharmacology 167 2003 115 122
39. A.W. Hartfield, N.A. Moore, and P.G. Clifton Effects of atypical antipsychotic drugs on intralipid intake and cocaine-induced hyperactivity in rats Neuropsychopharmacology 31 2006 1938 1945
40. J. Hauptman, C. Lucas, M.N. Boldrin, H. Collins, and K.R. Segal Orlistat in the long-term treatment of obesity in primary care settings Arch. Fam. Med. 9 2000 160 167
41. D.J. Heal, and E. Jagger Development, regulatory and marketing challenges for novel anti-obesity therapies J. Antel, N. Finer, D.J. Heal, G. Krause, Obesity and Metabolic Disorders 2005 IOS Amsterdam 73 91
42. D.J. Heal, J. Gosden, and S.L. Smith Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders Br. J. Clin. Pharmacol. 68 2009 861 874
43. 6 receptor as a target for developing novel anti-obesity drugs F. Borsini, International Review of Neurobiology vol. 96 2011 Academic Press Oxford 73 109
44. H.C. Jackson, A.M. Needham, L.J. Hutchins, S.E. Mazurkiewicz, and D.J. Heal Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat Br. J. Pharmacol. 121 1997 1758 1762
45. H.C. Jackson, K. Dickinson, R.B. Jones, C. Schumacher, and C. Jensen Comparison of the Effects of Sibutramine and Orlistat on Body Weight, Food and Water Intake and Body Composition in Dietary-Induced Obese Rats 2004 Neuroscience Abstract San Diego, CA Online
46. H.C. Jackson, S.C. Cheetham, K. Dickinson, R.B. Jones, D.J. Heal, P. Gregory, J. Antel, and A. McCreary Comparison of the Effects of Rimonabant and Sibutramine in a Rat Model of Dietary-Induced Obesity 2005 Neuroscience Abstract Washington, DC Online
47. H.C. Jackson, S.C. Cheetham, P.C. Gregory, and J. Antel Effect of Chronic Administration of Topiramate and Phentermine, Alone and in Combination, in an Animal Model of Dietary-Induced Obesity 629.15 2007 Neuroscience Abstract San Diego, CA Online
48. W.P.T. James, A. Astrup, N. Finer, J. Hilsted, P. Kopelman, S. Rössner, W.H. Saris, and L.F. Van Gaal Effect of sibutramine on weight maintenance after weight loss: a randomised trial Lancet 356 9248 2000 2119 2125
49. W.P. James, I.D. Caterson, W. Coutinho, N. Finer, L.F. Van Gaal, A.P. Maggioni, C. Torp-Pedersen, A.M. Sharma, G.M. Shepherd, R.A. Rode, C.L. Renz, and SCOUT Investigators Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects N. Engl. J. Med. 363 2010 905 917
50. P.M. Johnson, and P.J. Kenny Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats Nat. Neurosci. 13 2010 635 641
51. A.J. Kennedy, K.L.J. Ellacott, V.L. King, and A.H. Hasty Mouse models of the metabolic syndrome Dis. Model. Mech. 3 2010 156 166
52. P.J. Kenny Reward mechanisms in obesity, new insights and future directions Neuron 69 2011 664 679
53. D.C. Klonoff, J.B. Buse, L.L. Nielsen, X. Guan, C.L. Bowlus, J.H. Holcombe, M.E. Wintle, and D.G. Maggs Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years Curr. Med. Res. Opin. 24 2008 275 286
54. Z. Li, M. Maglione, W. Tu, W. Mojica, D. Arterburn, L.R. Shugarman, L. Hilton, M. Suttorp, V. Solomon, P.G. Shekelle, and S.C. Morton Meta-analysis, pharmacologic treatment of obesity Ann. Intern. Med. 142 2005 532 546
55. Y.L. Liu, I.P. Connoley, J. Harrison, D.J. Heal, and M.J. Stock Comparison of the thermogenic and hypophagic effects of sibutramine's metabolite 2 and other monoamine reuptake inhibitors Eur. J. Pharmacol. 452 2002 49 56
56. Y.L. Liu, D.J. Heal, and M.J. Stock Mechanism of the thermogenic effect of metabolite 2 (BTS 54 505), a major pharmacologically active metabolite of the novel anti-obesity drug, sibutramine Int. J. Obes. Relat. Metab. Disord. 26 2002 1245 1253
57. M. Maffei, J. Halaas, E. Ravussin, R.E. Pratley, G.H. Lee, Y. Zhang, H. Fei, S. Kim, R. Lallone, S. Ranganathan, P.A. Kern, and J. Friedman Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects Nat. Med. 1 1995 1155 1161
58. C.K. Martin, L.M. Redman, J. Zhang, M. Sanchez, C.M. Anderson, S.R. Smith, and E. Ravussin Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure J. Clin. Endocrinol. Metab. 3 2011 837 845
59. S.E. Nissen, S.J. Nicholls, K. Wolski, R. Nesto, S. Kupfer, A. Perez, H. Jure, R. De Larochellière, C.S. Staniloae, K. Mavromatis, J. Saw, B. Hu, A.M. Lincoff, and E.M. Tuzcu Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes, the PERISCOPE randomized controlled trial J. Am. Med. Assoc. 299 2008 1561 1573
60. Z. Pang, N.N. Wu, and W. Zhao The central cannabinoid CB1 receptor is required for diet-induced obesity and Rimonabant's antiobesity effects in mice Obesity (Silver Spring) 19 2011 1923 1934
61. F.X. Pi-Sunyer, L.J. Aronne, H.M. Heshmati, J. Devin, and J. Rosenstock Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America, a randomized controlled trial J. Am. Med. Assoc. 295 2006 761 775
62. P. Pramyothin, and L. Khaodhiar Metabolic syndrome with the atypical antipsychotics Curr. Opin. Endocrinol. Diabetes. Obes. 17 2010 460 466
63. W.E. Pratt, and M.E. Connolly Contrasting effects of systemic and central sibutramine administration on the intake of a palatable diet in the rat Neurosci. Lett. 484 2010 30 34
64. Qnexa NDA. 2010. http://www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/drugs/ endocrinologicandmetabolicdrugsadvisorycommittee/ucm218824.pdf.
65. R.E. Ratner, D. Maggs, L.L. Nielsen, A.H. Stonehouse, T. Poon, and B. Zhang Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus Diabetes. Obes. Metab. 8 2006 419 428
66. C. Ravinet Trillou, M. Arnone, C. Delgorge, N. Gonalons, P. Keane, J.P. Maffrand, and P. Soubrie Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice Am. J. Physiol. Regul. Integr. Comp. Physiol. 284 2003 R345 R353
67. M.C. Riddle, R.R. Henry, T.H. Poon, B. Zhang, S.M. Mac, and J.H. Holcombe Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin Diabetes. Metab. Res. Rev. 22 2006 483 491
68. R.J. Rodgers, P. Holch, and A.J. Tallet, t Behavioural satiety sequence (BSS), separating wheat from chaff in the behavioural pharmacology of appetite Pharmacol. Biochem. Behav. 97 2010 3 14
69. J. Rosenstock, L.J. Klaff, S. Schwartz, J. Northrup, J.H. Holcombe, and K. Wilhelm Effects of exenatide and lifestyle modification on bodyweight and glucose tolerance in obese subjects with and without pre-diabetes Diabetes. Care. 33 2010 1173 1175
70. 1B/2C agonists in rats Psychopharmacology 156 2001 108 114
71. N.E. Rowland, M. Mukherjee, and K. Robertson Effects of the cannabinoid receptor antagonist SR141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats Psychopharmacology 159 2001 111 116
72. 2C receptors in the hypophagic effect of m-CPP, ORG 37684 and CP-94,253 in the rat Prog. Neuropsychopharmacol. Biol. Psychiatry. 26 2002 441 449
73. P. Shah, and S. Mudaliar Pioglitazone, side effect and safety profile Expert. Opin. Drug. Saf. 9 2010 347 354
74. M.J. Skill, K. Dickinson, R.B. Jones, and D.J. Heal Thermogenic effect of repeated sibutramine treatment in female wistar rats Int. J. Obes. 24 2000 S135 Abstract 442
75. B.M. Smith, J.M. Smith, and J.H. Tsai Discovery and structure-activity relationship of (1R)-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity J. Med. Chem. 51 2008 305 313
76. S.R. Smith, N.J. Weissman, C.M. Anderson, M. Sanchez, E. Chuang, S. Stubbe, H. Bays, and W.R. Shanahan Multicenter, placebo-controlled trial of lorcaserin for weight management. Behavioral modification and lorcaserin for overweight and obesity management (BLOOM) study group N. Engl. J. Med. 363 2010 245 256
77. M.J. Stock An automatic, closed-circuit oxygen consumption apparatus for small animals J. Appl. Phys. 39 1975 849 850
78. B.A. Swinburn, G. Sacks, S.K. Lo, K.R. Westerterp, E.C. Rush, M. Rosenbaum, A. Luke, D.A. Schoeller, J.P. DeLany, N.F. Butte, and E. Ravussin Estimating the changes in energy flux that characterize the rise in obesity prevalence Am. J. Clin. Nutr. 89 2009 1723 1728
79. N. Takeda, S. Hasegawa, M. Morita, and T. Matsunaga Pica in rats is analogous to emesis, an animal model in emesis research Pharmacol. Biochem. Behav. 45 1993 817 821
80. N. Takeda, S. Hasegawa, M. Morita, A. Horii, A. Uno, A. Yamatodani, and T. Matsunaga Neuropharmacological mechanisms of emesis. I. Effects of antiemetic drugs on motion- and apomorphine-induced pica in rats Methods. Find. Exp. Clin. Pharmacol. 17 1995 589 596
81. W.J. Thomsen, A.J. Grottick, F. Menzaghi, H. Reyes-Saldana, S. Espitia, D. Yuskin, K. Whelan, M. Martin, M. Morgan, W. Chen, H. Al-Shamma, B. Smith, D. Chalmers, and D. Behan Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization J. Pharmacol. Exp. Ther. 325 2008 577 587
82. The NHS Information Centre Statistics on Obesity, Physical Activity and Diet, England 2010 http://www.ic.nhs.uk/webfiles/publications/opad10/Statistics- on-Obesity-Physical-Activity-and-Diet-England-2010.pdf
83. Z.D. Thornton-Jones, G.A. Kennett, K.R. Benwell, D.F. Revell, A. Misra, D.M. Sellwood, S.P. Vickers, and P.G. Clifton The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake Pharmacol. Biochem. Behav. 84 2006 353 359
84. Y.H. Tseng, A.M. Cypess, and C.R. Kahn Cellular bioenergetics as a target for obesity therapy Nat. Rev. Drug. Discov. 9 2010 465 482
85. A.N. Verty, A.M. Allen, and B.J. Oldfield The effects of rimonabant on brown adipose tissue in rat, implications for energy expenditure Obesity (Silver Spring) 17 2009 254 261
86. S.P. Vickers, P.G. Clifton, and C.T. Dourish Behavioural evidence that d-fenfluramine-induced anorexia in the rat is not mediated by the 5-HT1A receptor subtype Psychopharmacology 125 1996 168 175
87. S.P. Vickers, P.G. Clifton, C.T. Dourish, and L.H. Tecott Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor mutant mice Psychopharmacology (Berl) 143 1999 309 314
88. S.P. Vickers, C.T. Dourish, and G.A. Kennett Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors Neuropharmacology 41 2001 200 209
89. S.P. Vickers, L.J. Webster, A. Wyatt, C.T. Dourish, and G.A. Kennett Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats Psychopharmacology (Berl) 167 2003 103 111
90. S.P. Vickers, H.C. Jackson, and S.C. Cheetham The utility of animal models to evaluate novel anti-obesity agents Br. J. Pharmacol. 164 2011 1248 1262
91. Vivus Pipeline, 2011. http://www.vivus.com.
92. T.A. Wadden, J.P. Foreyt, G.D. Foster, J.O. Hill, S. Klein, P.M. O'Neil, M.G. Perri, F.X. Pi-Sunyer, C.L. Rock, J.S. Erickson, H.N. Maier, D.D. Kim, and E. Dunayevich Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification, the COR-BMOD trial Obesity (Silver Spring) 19 2011 110 120
93. S.B. Waters, B.G. Topp, S.Q. Siler, and C.M. Alexander Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion J. Diabetes. Sci. Technol. 3 2009 68 82
94. K. Weston-Green, X.F. Huang, and C. Deng Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats Behav. Brain. Res. 217 2011 337 346
95. C.M. Williams, P.J. Rogers, and T.C. Kirkham Hyperphagia in pre-fed rats following oral delta9-THC Physiol. Behav. 65 1998 343 346
96. P. Winn, S.F. Williams, and L.J. Herberg Feeding stimulated by very low doses of d-amphetamine administered systemically or by microinjection into the striatum Psychopharmacology (Berl) 78 1982 336 341
97. World Health Organisation Obesity and Overweight, Factsheet No 311 Geneva 2006 http://www.who.int/mediacentre/factsheets/fs311/en/index.html
98. E.P. Zorrilla, K. Inoue, E.M. Fekete, A. Tabarin, G.R. Valdez, and G.F. Koob Measuring meals, structure of prandial food and water intake of rats Am. J. Physiol. Regul. Integr. Comp. Physiol. 288 2005 R1450 R1467